Adjuvant application of interferons.
作者信息
el Kassas H, Kirkwood J M
机构信息
Division of Medical Oncology, University of Pittsburgh Cancer Institute, PA, USA.
出版信息
Semin Oncol. 1996 Dec;23(6):737-43.
PMID:8970596
Abstract
摘要
相似文献
1
Adjuvant application of interferons.
Semin Oncol. 1996 Dec;23(6):737-43.
2
Adjuvant treatment of melanoma using placebo or no therapies as control-arm: is it ethically correct?
Melanoma Res. 1999 Oct;9(5):528-9.
3
Emerging therapies for melanoma.
Expert Rev Anticancer Ther. 2008 Apr;8(4):553-60. doi: 10.1586/14737140.8.4.553.
4
Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
J Immunother. 2009 Jul-Aug;32(6):632-7. doi: 10.1097/CJI.0b013e3181a7d60d.
5
Systemic therapy for cutaneous melanoma.
Clin Plast Surg. 2010 Jan;37(1):127-46. doi: 10.1016/j.cps.2009.07.008.
6
Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma.
Semin Oncol. 1993 Dec;20(6 Suppl 9):27-32.
7
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.
J Clin Oncol. 2013 Oct 20;31(30):3831-7. doi: 10.1200/JCO.2012.47.9303. Epub 2013 Sep 9.
8
Adjuvant interferon in melanoma - a resurrection?
Br J Cancer. 2001 May 4;84(9):1141-2. doi: 10.1054/bjoc.2001.1798.
9
Multidisciplinary treatment of primary melanoma.
Surg Clin North Am. 2009 Feb;89(1):267-81, xi. doi: 10.1016/j.suc.2008.11.002.
10
Melanoma.
Cancer Chemother Biol Response Modif. 2001;19:629-38.
引用本文的文献
1
GM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease.
Virol J. 2011 Jan 9;8:7. doi: 10.1186/1743-422X-8-7.
2
Systemic therapy of malignant melanoma.
Med Oncol. 1997 Jun;14(2):73-81. doi: 10.1007/BF02990951.
Zotero 插件